Please login to the form below

Not currently logged in


This page shows the latest ALN-PCS news and features for those working in and with pharma, biotech and healthcare.

Alnylam predicts big things for its PCSK9 inhibitor ALN-PCS

Alnylam predicts big things for its PCSK9 inhibitor ALN-PCS

ALN-PCSsc to eventually lead the market, despite trailing its rivals by several years. ... The success in the ongoing phase I trial means that clinical development of ALN-PCS is now taken over by The Medicines Company (TMC), which licensed rights to the

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...